[1] Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095-128.
[2] Arredondo A, Aviles R. Costs and epidemiological changes of chronic diseases: implications and challenges for health systems. PloS one. 2015;10:e0118611.
[3] International Diabetes Federation. IDF Diabetes Atlas Ninth edition, acessed 16 jun 2020 in https://www.diabetesatlas.org/en/. 2019.
[4] Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes research and clinical practice. 2010;87:4-14.
[5] Brasil. VIGITEL Brasil 2017 Vigilância de fatores de risco e proteção para doenças crônicas por inquérito telefônico. Acessed in 08 april 2018 in https://bvsms.saude.gov.br/bvs/publicacoes/vigitel_brasil_2017_vigilancia_fatores_riscos.pdf. 2017.
[6] Malta DC, Duncan BB, Schmidt MI, Machado IE, Silva AG, Bernal RTI, et al. Prevalence of diabetes mellitus as determined by glycated hemoglobin in the Brazilian adult population, National Health Survey. REV BRAS EPIDEMIOL. 2019;22: E190006.
[7] Schmidt MI, Hoffmann JF, de Fatima Sander Diniz M, Lotufo PA, Griep RH, Bensenor IM, et al. High prevalence of diabetes and intermediate hyperglycemia - The Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Diabetology & metabolic syndrome. 2014;6:123.
[8] Mendes AB, Fittipaldi JA, Neves RC, Chacra AR, Moreira ED, Jr. Prevalence and correlates of inadequate glycaemic control: results from a nationwide survey in 6,671 adults with diabetes in Brazil. Acta diabetologica. 2010;47:137-45.
[9] Gomes MB, Coral M, Cobas RA, Dib SA, Canani LH, Nery M, et al. Prevalence of adults with type 1 diabetes who meet the goals of care in daily clinical practice: a nationwide multicenter study in Brazil. Diabetes research and clinical practice. 2012;97:63-70.
[10] Gomes MB, Gianella D, Faria M, Tambascia M, Fonseca RM, Rea R, et al. Prevalence of Type 2 diabetic patients within the targets of care guidelines in daily clinical practice: a multi-center study in Brazil. The review of diabetic studies : RDS. 2006;3:82-7.
[11] Saraiva JFK, Hissa MN, Felício JS, Cavalcanti CAJ, Saraiva GL, Piha T, et al. Diabetes Mellitus in Brazil: clinical characteristics, standard treatment choice and cost. J Bras Econ Saúde. 2016;8:80-90.
[12] Bahia LR, Araujo DV, Schaan BD, Dib SA, Negrato CA, Leao MP, et al. The costs of type 2 diabetes mellitus outpatient care in the Brazilian public health system. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2011;14:S137-40.
[13] Lindstrom J, Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes care. 2003;26:725-31.
[14] Meijnikman AS, De Block CE, Verrijken A, Mertens I, Corthouts B, Van Gaal LF. Screening for type 2 diabetes mellitus in overweight and obese subjects made easy by the FINDRISC score. Journal of diabetes and its complications. 2016;30:1043-9.
[15] Meijnikman AS, De Block CEM, Verrijken A, Mertens I, Van Gaal LF. Predicting type 2 diabetes mellitus: a comparison between the FINDRISC score and the metabolic syndrome. Diabetology & metabolic syndrome. 2018;10:12.
[16] Makrilakis K, Liatis S, Grammatikou S, Perrea D, Stathi C, Tsiligros P, et al. Validation of the Finnish diabetes risk score (FINDRISC) questionnaire for screening for undiagnosed type 2 diabetes, dysglycaemia and the metabolic syndrome in Greece. Diabetes & metabolism. 2011;37:144-51.
[17] Stiglic G, Fijacko N, Stozer A, Sheikh A, Pajnkihar M. Validation of the Finnish Diabetes Risk Score (FINDRISC) questionnaire for undiagnosed type 2 diabetes screening in the Slovenian working population. Diabetes research and clinical practice. 2016;120:194-7.
[18] Sociedade Brasileira de Diabetes. Diretrizes da Sociedade Brasileira de Diabetes 2017-2018. 2017.
[19] Krass I, Armour CL, Mitchell B, Brillant M, Dienaar R, Hughes J, et al. The Pharmacy Diabetes Care Program: assessment of a community pharmacy diabetes service model in Australia. Diabetic medicine : a journal of the British Diabetic Association. 2007;24:677-83.
[20] Fikri-Benbrahim N, Martinez-Martinez F, Saez-Benito L, Luque BS, Corpas JP, Moullin JC, et al. Assessment of a screening protocol for type 2 diabetes in community pharmacy. The DiabNow Study. Diabetes research and clinical practice. 2015;108:e49-52.
[21] Hersberger KE, Botomino A, Mancini M, Bruppacher R. Sequential screening for diabetes--evaluation of a campaign in Swiss community pharmacies. Pharmacy world & science : PWS. 2006;28:171-9.
[22] Papastergiou J, Folkins C, Li W. Community pharmacy-based A1c screening: a Canadian model for diabetes care. The International journal of pharmacy practice. 2016;24:189-95.
[23] Willis A, Rivers P, Gray LJ, Davies M, Khunti K. The effectiveness of screening for diabetes and cardiovascular disease risk factors in a community pharmacy setting. PloS one. 2014;9:e91157.
[24] Brasil. Lei no. 13.021, de 08 de agosto de 2014. Dispõe sobre o exercício e a fiscalização das atividades farmacêuticas. Diário Oficial da União, Poder Executivo, Brasília, DF, 11 ago. 2014a. Seção 1, p. 1, Edição Extra. 2014.
[25] Anvisa. Resolução RDC no 44, de 17 de agosto de 2009. Dispõe sobre Boas Práticas Farmacêuticas para o controle sanitário do funcionamento, da dispensação e da comercialização de produtos e da prestação de serviços farmacêuticos em farmácias e drogarias e dá outras providências. 2009.
[26] IBGE. Projection of the Brazilian population acessed in 15 jan 2017 in https://www.ibge.gov.br/apps/populacao/projecao/. 2017.
[27] International Diabetes Federation. IDF Diabetes Atlas Ninth edition, acessed 14 jan 2018 in https://www.diabetes.org.br/profissionais/images/2018/poster-atlas-idf-2017.pdf. 2017.
[28] World Health Oganization. The legal and regulatory framework for community pharmacies in the WHO European Region. 100p. 2019.
[29] Conselho Federal de Farmácia. November blue diabetes campaign https://www.cff.org.br/pagina.php?id=826 Accessed 10 Jun 2020. 2018.
[30] Conselho Federal de Farmácia. November blue diabetes campaign official website http://www.diabetes.cff.org.br/ Accessed 10 Jun 2020. 2018.
[31] Barim EM, McLellan KCP, Ribeiro RS, Carvalho JAM, Lindström J, Tuomilehto J, et al. Translation and cultural adaptation into Brazilian Portuguese of the Finnish Diabetes Risk Score (FINDRISC) and reliability assessment. REV BRAS EPIDEMIOL. 2020;23.
[32] ABESO. Associação Brasileira para o Estudo da Obesidade e da Síndrome Metabólica Diretrizes brasileiras de obesidade Acessed in 10 jan 2018 in https://abeso.org.br/wp-content/uploads/2019/12/Diretrizes-Download-Diretrizes-Brasileiras-de-Obesidade-2016.pdf. 2016.
[33] World Health Oganization. Data Global status report on noncommunicable diseases 2014.Switzerland: WHO Library Cataloguing-in-Publication Data.Available in: acessed 16 jun 2020 in https://apps.who.int/iris/bitstream/handle/10665/148114/ 9789241564854_eng.pdf;jsessionid=7164ABD7E36ECA51992A1C50FA8FCF6B?sequence=1. 2014.
[34] Rhee EJ. Nonalcoholic Fatty Liver Disease and Diabetes: An Epidemiological Perspective. Endocrinology and metabolism. 2019;34:226-33.
[35] Stefan N, Haring HU, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. The lancet Diabetes & endocrinology. 2019;7:313-24.
[36] Dias PC, Henriques P, Anjos LA, Burlandy L. Obesity and public policies: the Brazilian government’s definitions and strategies. Cad Saúde Pública 2017;33:1-12.
[37] Brasil. VIGITEL Brasil 2018 Vigilância de fatores de risco e proteção para doenças crônicas por inquérito telefônico. Acessed in april 2019 in https://portalarquivos2.saude.gov.br/images/pdf/2019/julho/25/vigitel-brasil-2018.pdf. 2018.
[38] Cepas V, Collino M, Mayo JC, Sainz RM. Redox Signaling and Advanced Glycation Endproducts (AGEs) in Diet-Related Diseases. Antioxidants. 2020;9.
[39] Nowotny K, Jung T, Hohn A, Weber D, Grune T. Advanced glycation end products and oxidative stress in type 2 diabetes mellitus. Biomolecules. 2015;5:194-222.
[40] Kowluru RA, Kanwar M. Effects of curcumin on retinal oxidative stress and inflammation in diabetes. Nutrition & metabolism. 2007;4:8.
[41] Kaul K, Hodgkinson A, Tarr JM, Kohner EM, Chibber R. Is inflammation a common retinal-renal-nerve pathogenic link in diabetes? Current diabetes reviews. 2010;6:294-303.
[42] Herder C, Roden M, Ziegler D. Novel Insights into Sensorimotor and Cardiovascular Autonomic Neuropathy from Recent-Onset Diabetes and Population-Based Cohorts. Trends in endocrinology and metabolism: TEM. 2019;30:286-98.
[43] Kruit A, Zanen P. The association between vitamin D and C-reactive protein levels in patients with inflammatory and non-inflammatory diseases. Clinical biochemistry. 2016;49:534-7.
[44] Pittas AG, Jorde R, Kawahara T, Dawson-Hughes B. Vitamin D supplementation for prevention of type 2 diabetes mellitus. To D or not to D? The Journal of clinical endocrinology and metabolism. 2020.
[45] Passos VM, Barreto SM, Diniz LM, Lima-Costa MF. Type 2 diabetes: prevalence and associated factors in a Brazilian community--the Bambui health and aging study. Sao Paulo medical journal = Revista paulista de medicina. 2005;123:66-71.
[46] Mayer-Davis EJ, D'Agostino R, Jr., Karter AJ, Haffner SM, Rewers MJ, Saad M, et al. Intensity and amount of physical activity in relation to insulin sensitivity: the Insulin Resistance Atherosclerosis Study. Jama. 1998;279:669-74.
[47] Alberti KG, Zimmet P, Shaw J. International Diabetes Federation: a consensus on Type 2 diabetes prevention. Diabetic medicine : a journal of the British Diabetic Association. 2007;24:451-63.
[48] Kirpichnikov D, Sowers JR. Diabetes mellitus and diabetes-associated vascular disease. Trends in endocrinology and metabolism: TEM. 2001;12:225-30.
[49] Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension. 2001;37:1053-9.
[50] Fornos-Perez JA, Andres-Rodriguez NF, Andres-Iglesias JC, Luna-Cano R, Garcia-Soidan J, Lorenzo-Veiga B, et al. Detection of people at risk of diabetes in community pharmacies of Pontevedra (Spain) (DEDIPO). Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion. 2016;63:387-96.
[51] Dhippayom T, Fuangchan A, Tunpichart S, Chaiyakunapruk N. Opportunistic screening and health promotion for type 2 diabetes: an expanding public health role for the community pharmacist. Journal of public health. 2013;35:262-9.
[52] Bovet P, Hirsiger P, Emery F, De Bernardini J, Rossier C, Trebeljahr J, et al. Impact and cost of a 2-week community-based screening and awareness program for diabetes and cardiovascular risk factors in a Swiss canton. Diabetes, metabolic syndrome and obesity : targets and therapy. 2011;4:213-23.
[53] Chaturvedi N. The burden of diabetes and its complications: trends and implications for intervention. Diabetes research and clinical practice. 2007;76 Suppl 1:S3-12.
[54] Saaristo T, Peltonen M, Keinanen-Kiukaanniemi S, Vanhala M, Saltevo J, Niskanen L, et al. National type 2 diabetes prevention programme in Finland: FIN-D2D. International journal of circumpolar health. 2007;66:101-12.
[55] Grisold A, Callaghan BC, Feldman EL. Mediators of diabetic neuropathy: is hyperglycemia the only culprit? Current opinion in endocrinology, diabetes, and obesity. 2017;24:103-11.
[56] Sociedade Brasileira de Diabetes. Diretrizes Sociedade Brasileira de Diabetes 2019-2020 Acessed in jun 2020 in https://www.diabetes.org.br/profissionais/images/DIRETRIZES-COMPLETA-2019-2020.pdf. 2019.
[57] Fazel MT, Bagalagel A, Lee JK, Martin JR, Slack MK. Impact of Diabetes Care by Pharmacists as Part of Health Care Team in Ambulatory Settings: A Systematic Review and Meta-analysis. The Annals of pharmacotherapy. 2017;51:890-907.
[58] Correr CJ, Melchiors AC, Fernandez-Llimos F, Pontarolo R. Effects of a pharmacotherapy follow-up in community pharmacies on type 2 diabetes patients in Brazil. International journal of clinical pharmacy. 2011;33:273-80.
[59] Pousinho S, Morgado M, Falcao A, Alves G. Pharmacist Interventions in the Management of Type 2 Diabetes Mellitus: A Systematic Review of Randomized Controlled Trials. Journal of managed care & specialty pharmacy. 2016;22:493-515.
[60] Barcelo A, Arredondo A, Gordillo-Tobar A, Segovia J, Qiang A. The cost of diabetes in Latin America and the Caribbean in 2015: Evidence for decision and policy makers. Journal of global health. 2017;7:020410.
[61] Menzin J, Langley-Hawthorne C, Friedman M, Boulanger L, Cavanaugh R. Potential short-term economic benefits of improved glycemic control: a managed care perspective. Diabetes care. 2001;24:51-5.
[62] Georg AE, Duncan BB, Toscano CM, Schmidt MI, Mengue S, Duarte C, et al. Economic analysis of a screening program for diabetes mellitus in Brazil. Rev Saúde Pública. 2005;39:452-60.
[63] Conselho Federal de Farmácia. Resolução n° 585, de 29 de Agosto de 2013. Diário Oficial da União. 2013.
[64] IBGE. Brazil in summary, education, years of study. https://brasilemsintese.ibge.gov.br/educacao/anos-de-estudo.html Acessed in 01 of september of 2020 2020.